{{Short description|American physician and oncologist}} {{Orphan|date=January 2022}} {{Infobox scientist | name = Beth Overmoyer | workplaces = Hospital of the University of Pennsylvania <br> Dana–Farber Cancer Institute <br> Harvard Medical School | alma_mater = Case Western Reserve University }} '''Beth Ann Overmoyer''' (born 1960) is an American physician and oncologist. She is Director of the Inflammatory Breast Cancer Program at the Dana–Farber Cancer Institute.
== Early life and education == Overmoyer was an undergraduate student in biology and graduated magna cum laude.<ref name=":0">{{Cite book|last1=Program|first1=Committee to Review the Department of Defense's Breast Cancer Research|url=https://books.google.com/books?id=t1luAgAAQBAJ&dq=national+academy+of+medicine+Beth+Overmoyer&pg=PT149|title=A Review of the Department of Defense's Program for Breast Cancer Research|last2=Medicine|first2=Institute of|date=1997-08-14|publisher=National Academies Press|isbn=978-0-309-59052-5|language=en}}</ref> She was a medical student at the Case Western Reserve University,<ref name=":1">{{Cite web|title=Dr. Beth Overmoyer {{!}} Clinician + Researcher {{!}} IBC-IC|url=https://ibcic.org/researcher/beth-overmoyer/|access-date=2022-01-04|website=Inflammatory Breast Cancer International Consortium {{!}} IBC-IC|language=en-US}}</ref> before moving to the University of Pennsylvania for her internship and medical residency. She became interested in oncology in the late eighties, when she started researching breast cancer at the Hospital of the University of Pennsylvania.<ref name=":0"/>
== Research and career == Overmoyer was appointed to the Cleveland Clinic,{{when|date=January 2022}} where she was made the hospital director of breast cancer.<ref name="newstimes.com">{{Cite web|last=CT)|first=News-Times, The (Danbury|date=2005-05-02|title='The best of both worlds'|url=https://www.newstimes.com/news/article/The-best-of-both-worlds-245587.php|access-date=2022-01-04|website=NewsTimes|language=en-US}}</ref> She dedicated her career to breast cancer prevention and the treatment of early-stage disease.<ref>{{Cite journal|last=Overmoyer|first=Beth|date=2003-02-15|title=Combination Chemotherapy for Metastatic Breast Cancer: Reaching for the Cure|url=http://ascopubs.org/doi/10.1200/JCO.2003.10.085|journal=Journal of Clinical Oncology|language=en|volume=21|issue=4|pages=580–582|doi=10.1200/JCO.2003.10.085|pmid=12586790|issn=0732-183X|url-access=subscription}}</ref> Alongside leading several clinical trials, early in her career she was involved with a review into the United States Department of Defense funding for breast cancer research.<ref>{{Cite web|title=A Review of the Department of Defense's Program for Breast Cancer Research|url=http://www8.nationalacademies.org/onpinews/newsitem.aspx?RecordID=5808|access-date=2022-01-04|website=www8.nationalacademies.org|language=en}}</ref> She was one of the first to demonstrate high dose chemotherapy – autologous stem-cell transplantation to treat metastatic carcinoma.<ref name=":0"/><ref>{{Cite news|last=Grady|first=Denise|date=2000-06-25|title=PATIENT POWER; For Experimental Treatments, 'Somebody Has to Be First'|language=en-US|work=The New York Times|url=https://www.nytimes.com/2000/06/25/health/patient-power-for-experimental-treatments-somebody-has-to-be-first.html|access-date=2022-01-04|issn=0362-4331}}</ref>
In 2007,<ref name=":1"/> Overmoyer moved to the Dana–Farber Cancer Institute, where she established the Inflammatory Breast Cancer Program in 2009.<ref>{{Cite web|title=Inflammatory Breast Cancer Program - Dana–Farber Cancer Institute {{!}} Boston, MA|url=https://www.dana-farber.org/inflammatory-breast-cancer-program/|access-date=2022-01-04|website=www.dana-farber.org}}</ref> Inflammatory breast cancer is a rare, fast-growing disease, which causes the lymph vessels within breast skins to become clogged with tumor cells.<ref name=":2">{{Cite web|date=2018-06-11|title=What's the Latest in Inflammatory Breast Cancer Research? {{!}} Dana-Farber|url=https://blog.dana-farber.org/insight/2018/06/whats-latest-inflammatory-breast-cancer-research/|access-date=2022-01-04|website=Dana–Farber Cancer Institute|language=en-US}}</ref> Overmoyer established the Inflammatory Breast Cancer Registry, a repository of information and tumor samples to aid with the understanding and diagnosis of the disease.<ref name=":2"/> She showed that Ruxolitinib was capable of suppressing the inflammatory breast cancer pathway in patients with triple-negative breast cancer.<ref>{{Cite journal|last1=Stover|first1=Daniel G.|last2=Gil Del Alcazar|first2=Carlos R.|last3=Brock|first3=Jane|last4=Guo|first4=Hao|last5=Overmoyer|first5=Beth|last6=Balko|first6=Justin|last7=Xu|first7=Qiong|last8=Bardia|first8=Aditya|last9=Tolaney|first9=Sara M.|last10=Gelman|first10=Rebecca|last11=Lloyd|first11=Maxwell|date=2018-05-04|title=Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer|journal=npj Breast Cancer|language=en|volume=4|issue=1|page=10|doi=10.1038/s41523-018-0060-z|pmid=29761158|pmc=5935675|issn=2374-4677}}</ref>
Overmoyer studied the clinical benefits of Enobosarm (an androgen receptor modulator) in patients with androgen receptor positive and estrogen receptor positive breast cancer. She found that Enobosarm was well tolerated, safe and showed clinical benefit.<ref>{{Cite web|title=Enobosarm Shows Clinical Benefit in AR+, ER+ Metastatic Breast Cancer|url=https://www.onclive.com/view/enobosarm-shows-clinical-benefit-in-ar-er-metastatic-breast-cancer|access-date=2022-01-04|website=OncLive|date=22 December 2020 }}</ref>
She is also an assistant professor of medicine and Harvard Medical School.<ref name=":1" />
== Selected publications ==
* {{Cite Q|Q36024588}} * {{Cite Q|Q28256478}} * {{Cite Q|Q86680692}}
== References == {{reflist}}
{{authority control}}
{{DEFAULTSORT:Overmoyer, Beth}} Category:1960 births Category:Living people Category:American oncologists Category:Case Western Reserve University alumni Category:American women medical doctors Category:Harvard Medical School faculty Category:20th-century American medical doctors Category:21st-century American medical doctors